# Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

> **NCT04082910** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor
- Hematological Malignancy

## Interventions

- **DRUG:** Metoprolol
- **DRUG:** metoprolol, infliximab, etanercept, tocilizumab and/or other agents

## Key facts

- **NCT ID:** NCT04082910
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-15
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082910, "Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04082910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*